Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cipla
US Army
Harvard Business School
Daiichi Sankyo
US Department of Justice
Queensland Health
McKesson
Mallinckrodt

Generated: July 18, 2018

DrugPatentWatch Database Preview

Actavis Labs Company Profile

« Back to Dashboard

What is the competitive landscape for ACTAVIS LABS, and what generic and branded alternatives to ACTAVIS LABS drugs are available?

ACTAVIS LABS has one hundred and nine approved drugs.

There are three tentative approvals on ACTAVIS LABS drugs.

Summary for Actavis Labs
US Patents:0
Tradenames:84
Ingredients:75
NDAs:109

Drugs and US Patents for Actavis Labs

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Fl Inc NITROGLYCERIN nitroglycerin TABLET;SUBLINGUAL 203693-002 Oct 16, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Actavis Labs Fl Inc KETOPROFEN ketoprofen CAPSULE, EXTENDED RELEASE;ORAL 075270-002 Mar 24, 1999 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Actavis Labs Fl Inc CYCLOBENZAPRINE HYDROCHLORIDE cyclobenzaprine hydrochloride TABLET;ORAL 071611-003 Feb 3, 2006 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Actavis Labs Fl Inc ALPRAZOLAM alprazolam TABLET, EXTENDED RELEASE;ORAL 077198-004 May 13, 2010 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Actavis Labs

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Actavis Labs Ut Inc LOXITANE C loxapine hydrochloride CONCENTRATE;ORAL 017658-001 Approved Prior to Jan 1, 1982 3,546,226 ➤ Try a Free Trial
Actavis Labs Ut Inc LOXITANE C loxapine hydrochloride CONCENTRATE;ORAL 017658-001 Approved Prior to Jan 1, 1982 4,049,809 ➤ Try a Free Trial
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-001 Approved Prior to Jan 1, 1982 3,546,226 ➤ Try a Free Trial
Actavis Labs Ut Inc EMLA lidocaine; prilocaine CREAM;TOPICAL 019941-001 Dec 30, 1992 4,529,601 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ACTAVIS LABS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Department of Justice
Deloitte
Teva
Harvard Business School
Fish and Richardson
Daiichi Sankyo
Federal Trade Commission
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.